Antiviral effect of Cidofovir (cas 113852-37-2) on parvovirus B19 replication
-
Add time:08/29/2019 Source:sciencedirect.com
Parvovirus B19 (B19V) is a human ssDNA virus responsible for a wide range of clinical manifestations, still lacking for a specific antiviral therapy. The identification of compounds active against B19V may add therapeutic options to the treatment of B19V infections, that now entirely relies on symptomatic treatments. In the search for compounds possibly inhibiting B19V replication, a particular focus was raised to Cidofovir (cas 113852-37-2), an acyclic nucleoside phosphonate broadly active against dsDNA viruses. The present study was aimed at evaluating the effect of cidofovir against B19V in two model systems, the UT7/EpoS1 cell line and erythroid progenitor cells (EPC), generated from peripheral blood mononuclear cells. Experiments were carried out at different multiplicity of infections and cidofovir concentrations (0–500 μM) during a course of infection. The effects of cidofovir on B19V replication were assessed by qPCR assays while influence of cidofovir on host cells was measured by cell proliferation and viability assays. Our findings demonstrated that cidofovir has a relevant inhibiting activity on B19V replication within infected UT7/EpoS1, and that the effect on B19V DNA amounts is dose-dependent allowing for the determination of EC50 and EC90 values (7.45–41.27 μM, and 84.73–360.7 μM, respectively). In EPCs, that constitute a cellular population close to the natural target cells in bone marrow, the inhibitory effect was demonstrated to a lesser extent, however provoking a significant reduction on B19V DNA amounts at 500 μM (68.2–92.8%). To test infectivity of virus released from EPCs cultured in the presence of cidofovir, cell culture supernatants were used as inoculum for a further course of infection in UT7/EpoS1 cells, indicating a significant reduction in viral infectivity at 500 μM cidofovir. Since the drug did not interfere with the overall cellular DNA synthesis and metabolic activity, the observed effect of cidofovir could be likely related to a specific inhibition of B19V replication.
We also recommend Trading Suppliers and Manufacturers of Cidofovir (cas 113852-37-2). Pls Click Website Link as below: cas 113852-37-2 suppliers
Prev:Intralesional Cidofovir (cas 113852-37-2) injection for recurrent respiratory papillomatosis in Japan
Next:In vitro susceptibility to ST-246 and Cidofovir (cas 113852-37-2) corroborates the phylogenetic separation of Brazilian Vaccinia virus into two clades) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Degrees of Dysplasia Based on Viral Typing in Patients With Cidofovir (cas 113852-37-2) Use and Recurrent Respiratory Papillomatosis09/02/2019
- Clinical Research: Supportive CareCidofovir (cas 113852-37-2) in the Treatment of BK Virus–Associated Hemorrhagic Cystitis after Allogeneic Hematopoietic Stem Cell Transplantation09/01/2019
- Original breveTratamiento de verrugas anogenitales con Cidofovir (cas 113852-37-2) tópicoTreatment of anogenital warts with topical Cidofovir (cas 113852-37-2)08/31/2019
- In vitro susceptibility to ST-246 and Cidofovir (cas 113852-37-2) corroborates the phylogenetic separation of Brazilian Vaccinia virus into two clades08/30/2019
- Intralesional Cidofovir (cas 113852-37-2) injection for recurrent respiratory papillomatosis in Japan08/28/2019
- Treatment of intraurethral condylomata acuminata with surgery and Cidofovir (cas 113852-37-2) instillations in two immunocompromised patients and review of the literature08/27/2019
- Infectious DiseaseEfficacy of Cidofovir (cas 113852-37-2) in Treatment of BK Virus–Induced Hemorrhagic Cystitis in Allogeneic Hematopoietic Cell Transplant Recipients08/26/2019
- Cidofovir (cas 113852-37-2)☆08/25/2019
- Case reportAdenovirus pneumonia treated with Cidofovir (cas 113852-37-2) in an immunocompetent high school senior08/24/2019